Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks ...

Last year, China-based Jiangsu Hengrui Pharmaceuticals overtook the U.K.’s AstraZeneca as the top clinical trial sponsor in ...

Eli Lilly just struck a major deal with the world's largest retailer. GLP-1 drugs may have uses beyond obesity and diabetes ...

Anavex (AVXL) awaits a key EU ruling on its Alzheimer’s drug. Learn about trial challenges, approval risks, and why a Sell ...

New blood tests could help doctors diagnose Alzheimer's disease faster and more accurately, researchers reported Sunday – but ...

Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised ...

The survival rates of people with early onset dementia—diagnosed before the age of 65—vary considerably by clinical type, but sex, age, family history and co-existing conditions aren't specific risk ...

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply ...

Julianne Moore had an important message for people watching the World Series this week, and I was one of them. Maybe you saw it, too?

Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly’s global supply ...

Now, it’s worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 194% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...